Macropinocytosis in pancreatic ductal adenocarcinoma: From metabolic reprogramming to therapeutic targeting
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-11 · 1881 (6) · 189745
DOI: 10.1016/j.bbcan.2026.189745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-11. Verfasst von Jianjun Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, 3-17 Renmin South Road, Chengdu, Sichu…. Die Arbeit nennt 117 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC), driven by prevalent KRAS mutations and situated within a dense, desmoplastic microenvironment, remains one of the most lethal malignancies worldwide, underscoring an urgent need for effective therapeutic strategies. Emerging evidence has identified macropinocytosis-a non-selective endocytic pathway that scavenges extracellular nutrients-as a critical adaptive mechanism that enables PDAC to sustain cellular viability and metabolic homeostasis under nutrient-deprived and fibrotic conditions. Consequently, macropinocytosis has emerged as a promising therapeutic vulnerability. In this review, we outline the macropinocytic process and the key signaling networks that govern it in PDAC, including KRAS, PI3K, PTEN, YAP/TAZ, WNT/β-catenin, HIF-1α, NRF2, and PKC signaling. We examine how these molecular modulators cooperate to support macropinocytosis-dependent metabolic adaptation and discuss the contribution of macropinocytosis to PDAC initiation, progression, tumor microenvironment remodeling, and crosstalk with other nutrient salvage programs. Finally, we evaluate two contrasting strategies for targeting macropinocytosis-activation to enhance drug delivery or induce methuosis, versus inhibition to starve tumor cells of scavenged nutrients-and discuss the prospects and limitations of each approach for PDAC therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, 3-17 Renmin South Road, Chengdu, Sichuan 610041, PR China.
- Department of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, 3-17 Renmin South Road, Chengdu, Sichuan 610041, PR China. Electronic address: tzhu@scu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Chen, H., Qiu, S., & Zhu, T. (2026). Macropinocytosis in pancreatic ductal adenocarcinoma: From metabolic reprogramming to therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(6), 189745. https://doi.org/10.1016/j.bbcan.2026.189745
Vancouver
Yang J, Chen H, Qiu S, Zhu T. Macropinocytosis in pancreatic ductal adenocarcinoma: From metabolic reprogramming to therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(6):189745. doi:10.1016/j.bbcan.2026.189745
BibTeX
@article{Yang2026,
author = {Yang, Jianjun and Chen, Hongmei and Qiu, Shuoyu and Zhu, Tongbo},
title = {Macropinocytosis in pancreatic ductal adenocarcinoma: From metabolic reprogramming to therapeutic targeting},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {6},
pages = {189745},
doi = {10.1016/j.bbcan.2026.189745}
}
EUVIMED